|TARGETS:||Receptor tyrosine kinases including RET, CHR4q12, CBL, Trk, and DDR families.|
|INDICATIONS:||Solid tumors with an initial focus on Non-Small Cell Lung Cancer (NSCLC)|
|STATUS:||Phase 1B basket trial in patients with solid tumors, once daily oral dose|
Sitravatinib (MGCD516) is being evaluated in a Phase 1b dose expansion cohort in selected patients with specific genetic alterations that are drivers of tumor growth, with an initial focus on NSCLC and in other solid tumors where sitravatinib may confer a benefit. Sitravatinib is a tyrosine kinase inhibitor with demonstrated potent inhibition of a closely related spectrum of tyrosine kinases, including RET, CBL, CHR4q12, DDR and Trk, which are key regulators of signaling pathways that lead to cell growth, survival and tumor progression. Based on our experience to date, the PK is well-behaved and a convenient, once daily dosing regime is being explored.
Mirati owns the worldwide rights to Sitravatinib (MGCD516).
ASCO Genitourinary Cancers Symposium
World Conference on Lung Cancer 2017
Click to view “Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy”
Click to view “CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib”
IASLC 2017 CHICAGO
IASLC 2016 TiP Poster #4109
IASLC 2016 TiP Poster #4795
ASCO 2016 Poster #2575